Wnt Research: How a retraction delayed an IPO, shrunk investment — but should build public trust
It’s easy to focus on the downstream scientific effects of retractions. But sometimes they have financial implications, too. Two weeks ago, we covered the retraction of a PNAS paper on a potential breast cancer treatment, one that would make tumors that didn’t respond to tamoxifen respond to the drug. We learned earlier this week from … Continue reading Wnt Research: How a retraction delayed an IPO, shrunk investment — but should build public trust